RxDoctor Payments Data

Brandon Holley, PA

Physician Assistant · Tupelo, MSNPI 1770962698

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 202 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Johnson & Johnson at 26.0% of the total. Reporting peaked in 2023 at $922 and has fallen 80.6% since, to $179 in 2025.

$3,043in general payments, 2019–2025

Across 202 payments — averaging $15.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$793
  • Lundbeck LLC$509
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$489
  • Neurocrine Biosciences, Inc.$389
  • AbbVie$324
  • Alkermes, Inc.$179
  • plus $361 from 6 others

What the payments were for

  • Food & beverage$3,043100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,043 in reported general payments places this provider in the 75th percentile of 278 physician assistant providers in Mississippi.

See all physician assistant providers in Mississippi

Medicare billing

Part B allowed, 2024
$1,660
Medicare patients
12
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate40$108,193
TrintellixVortioxetine Hydrobromide24$14,433
Lurasidone Hcl21$4,215
Quetiapine Fumarate64$982
Divalproex Sodium32$819
Bupropion XlBupropion Hcl26$612
Buspirone Hcl32$583
Clonazepam36$460
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine12$457
Benztropine Mesylate31$442
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine13$390
Aripiprazole18$331
Quetiapine Fumarate ErQuetiapine Fumarate16$324
Mirtazapine28$294
Trazodone Hcl27$292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$793$108,19340 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$37$14,43324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 278 physician assistant providers in Mississippi.

Other physician assistant in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →